Probiotic Co-aggregation for Oral Pathogen Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to treating and preventing gingivitis and periodontitis in the oral cavity often fail to effectively balance the mouth microbiota, leading to nonspecific eradication of resident bacteria and inadequate suppression of inflammatory responses, with existing probiotic strains showing variable efficacy and limited ability to form co-aggregates with disease-associated bacteria such as Porphyromonas gingivalis, Porphyromonas endodontalis, Tannerella forsythia, Filifactor alocis, and Eubacterium saphenum.
Innovation Solution
A specific combination of probiotic microorganisms, including Lactobacillus delbrueckii subsp. lactis LL-G41, Lactobacillus fermentum 35D, Lactobacillus gasseri NS8, Lactobacillus salivarius NS13, Streptococcus salivarius NS18, and Streptococcus salivarius NS19, which form co-aggregates with these pathogens, reducing their load and inhibiting their growth, and are capable of reducing inflammatory factors like interleukin and TNF-α, are used in oral care compositions and products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If strong anti-bacterial properties are used in oral care products, then bacterial load is reduced, but beneficial bacteria are also eradicated and microbiota balance is disrupted
Solution Approach 1:
Instead of using anti-bacterial agents to kill bacteria, the invention uses probiotic bacteria that competitively displace pathogenic bacteria through co-aggregation. The beneficial bacteria actively bind to pathogens and form aggregates that are removed from the oral cavity, inverting the approach from eradication to competitive exclusion.
Solution Approach 2:
The probiotic bacteria serve as intermediaries that bind to pathogenic bacteria through co-aggregation. These intermediary organisms facilitate the removal of pathogens by forming aggregates that can be mechanically removed, rather than directly killing the pathogens with anti-bacterial agents.
2Reliability
If existing probiotic strains are used, then some anti-inflammatory effects are achieved, but efficacy varies strongly and aggregation ability with disease-associated species is limited
Solution Approach 1:
The invention changes the key parameter of aggregation ability by selecting and combining specific probiotic strains that have been demonstrated to have high aggregation indices with disease-associated bacteria. This parameter optimization ensures reliable anti-inflammatory effects through enhanced pathogen binding and removal capacity.
Solution Approach 2:
The invention creates a composite probiotic formulation containing multiple specific strains (Lactobacillus delbrueckii subsp. lactis LL-G41, Lactobacillus fermentum 35D, Lactobacillus gasseri NS8, Lactobacillus salivarius NS13, Streptococcus salivarius NS18, and Streptococcus salivarius NS19). This composite approach combines the aggregation abilities of different strains to achieve superior overall efficacy against various pathogenic species.
3Productivity
If mechanical removal of plaque is improved, then plaque accumulation is reduced, but inflammatory responses are not sufficiently suppressed at the tissue level
Solution Approach 1:
The probiotic bacteria act as intermediaries that directly interact with pathogenic bacteria at the tissue level. By forming co-aggregates with pathogens, they facilitate their removal and simultaneously reduce the production of pro-inflammatory mediators, addressing inflammation directly rather than only through mechanical plaque removal.
Solution Approach 2:
The invention converts the presence of pathogenic bacteria from a harmful factor into a beneficial process. The probiotic bacteria bind to pathogens and induce their aggregation and removal, while also modulating the immune response to reduce inflammation. This transforms the pathogen-bacteria interaction from a disease-causing mechanism into a therapeutic process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These strains effectively form co-aggregates with disease-associated bacteria, promoting their removal and reducing inflammation, thereby balancing the oral microbiota and preventing gingivitis and periodontitis, with demonstrated aggregation indices and inhibitory activities against key pathogens.
Implementation Method 1
the microorganism(s) is/are selected from the group consisting of Lactobacillus delbrueckii subsp. lactis LL-G41 (CCTCC M 2016652), Lactobacillus fermentum 35D (DSM 32130), Lactobacillus gasseri NS8 (NCIMB 11718), Lactobacillus salivarius NS13 (NCIMB 8816), Streptococcus salivarius NS18 (CBS 142430) and Streptococcus salivarius NS19 (CBS 142431) for use as probiotic agent for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis
Data Source
AI summary
The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, preferably for the treatment and/or prevention of gingivitis and/or peridontitis.In particular, the present invention relates to microorganisms or mixtures thereof for use as probiotic agents for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis.Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the probiotic microorganisms as active agents as well as a method of production thereof.